Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPA144 plus mFOLFOX6 vs placebo plus mFOLFOX6 in FGFR2‑selected gastric or gastroesophageal junction cancer
CTR20181245Phase 2Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bemarituzumab in gastric cancer (GC), esophagogastric junction cancer, sponsored by Five Prime Therapeutics, Inc.. Started Sep 2018; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20181245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181245.